YOLFTbeta
Minerva Neurosciences Inc

Minerva Neurosciences Inc

NERV · NASDAQ · Healthcare / Biotechnology

2.30USD-0.08 (-3.36%)

Price History

Full chart

Market Stats

Previous Close2.38
Open2.38
Day Range2.26 – 2.40
52-Week Range2.06 – 8.80
Volume74.46K
Market Cap162.34M
P/E (TTM)0.00
Forward P/E11.21
EPS-36.12
Dividend Yield0.00%
Beta-0.10
50-Day Avg4.28
200-Day Avg5.07

About

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Remy Luthringer Ph.D.
  • Employees7
  • Headquarters1500 District Avenue, Burlington, MA, United States, 01803, USA
  • Websitehttps://www.minervaneurosciences.com

Leadership

  • Dr. Remy Luthringer Ph.D.Executive Chairman, CEO & Member of Scientific Advisory Board · b. 1961
  • Mr. Frederick W. Ahlholm CPASenior VP, CFO & Secretary · b. 1966
  • Mr. Joseph ReillySenior VP & COO · b. 1975
  • Mr. Anthony AliquoChief Accounting Officer & Principal Accounting Officer · b. 1987
  • Mr. William B. BoniVice President of Investor Relations & Corporate Communications · b. 1952
  • Mr. James O'ConnorChief Business Officer & General Counsel · b. 1974
  • Prof. Michael Davidson M.D.Member of Scientific Advisory Board & Chief Medical Officer · b. 1950

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---0000041.18M41.18M00000
Growth (%)---------+0.00%-100.00%----
Cost of Revenue---017.28K16.53K11.09K17.47K161.51K176.18K101.79K8.51K30.98K22.47K5.44K
Gross Profit---0-17.28K-16.53K-11.09K-17.47K-162.00K41.18M-102.00K-8.51K-30.98K-22.47K-5.44K
Gross Margin---------0.39%100.00%-----
Operating Expense---54.87M26.09M30.17M41.16M51.71M75.70M39.33M45.26M25.22M23.09M21.83M15.10M
Operating Income-1.13M-1.58M-3.17M-54.87M-26.11M-30.19M-41.17M-51.73M-75.86M1.85M-45.37M-25.23M-23.12M-21.85M-15.10M
Operating Margin---------184.25%4.49%-----
EBITDA-1.12M-1.58M-3.20M-54.81M-26.01M-30.00M-40.27M-50.04M-74.28M2.12M-45.28M-24.69M-21.69M6.02M-293.42M
EBITDA Margin---------180.39%5.14%-----
Net Income-1.12M-1.58M-3.26M-56.90M-27.08M-31.05M-31.52M-50.17M-72.18M1.94M-49.91M-32.11M-30.01M1.44M-293.42M
Net Income Margin---------175.31%4.71%-----
R&D592.97K550.36K708.49K42.91M18.53M20.44M30.26M34.89M58.12M22.04M32.04M14.65M12.71M11.90M5.76M
R&D as % of Total Revenue--------141.16%53.52%-----
Interest Expense-059.61K2.05M1.05M1.03M614.26K110.45K1.59M06.33M7.41M8.28M4.56M0
Interest Expense % of Total Revenue--------3.86%0.00%-----

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-209.31K29.17M68.45M82.58M132.94M183.70M139.14M77.50M57.63M77.12M55.09M56.90M37.14M97.97M
Total Liabilities-190.29K9.00M16.95M27.26M26.96M52.10M48.87M49.72M4.96M69.15M75.11M85.36M62.84M238.72M
Total Equity-19.02K20.18M51.50M55.32M105.98M131.60M90.26M27.78M52.66M7.98M-20.02M-28.46M-25.69M-140.75M
Cash-200.31K1.82M18.55M14.28M82.98M26.05M50.23M21.41M25.36M60.76M36.09M40.91M21.36M82.30M
Total Debt--58.27K-9.94M8.69M3.96M-284.13K111.23K-73.73M82.02M60.00M64.96M
Net Debt--200.31K-1.76M-18.55M-4.35M-74.29M-22.09M-50.23M-21.13M-25.25M-60.76M-36.09M-40.91M-21.36M-17.34M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-908.54K-2.16M-35.96M-24.27M-25.69M3.09M-41.94M-43.43M-33.82M-24.60M-24.65M-14.78M-19.55M-13.51B
Investing Cash Flow--3.23K1.09M-18.33M17.82M-107.19M69.49M14.08M24.53M-16.33K-16.33K---
Financing Cash Flow900.00K3.78M51.60M38.34M76.57M47.17M-3.34M525.00K13.24M60.00M-519.60M074.45B
Capital Expenditure03.23K45.61K52.40K52.40K52.40K0316.33K16.33K16.33K200
Free Cash Flow-908.54K-2.16M-36.01M-24.27M-25.69M3.04M-41.94M-43.43M-33.82M-24.60M-24.66M-14.78M-19.55M-13.51B
Dividends Paid--00010.49M--------
FCF to OCF100.00%100.15%100.13%100.00%100.00%98.31%100.00%100.00%100.00%100.00%100.07%100.00%100.00%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%344.93%--------

Earnings

Report DateAug 7, 2014Nov 6, 2014Mar 26, 2015May 7, 2015Aug 5, 2015Nov 5, 2015Mar 14, 2016May 3, 2016Aug 4, 2016Nov 3, 2016Mar 13, 2017May 4, 2017Aug 3, 2017Nov 6, 2017Mar 12, 2018May 3, 2018Aug 2, 2018Nov 5, 2018Mar 12, 2019May 6, 2019Aug 5, 2019Nov 4, 2019Mar 9, 2020May 4, 2020Aug 3, 2020Nov 2, 2020Mar 8, 2021May 12, 2021Aug 2, 2021Nov 8, 2021Mar 1, 2022May 4, 2022Aug 9, 2022Nov 9, 2022Mar 8, 2023May 15, 2023Aug 1, 2023Nov 6, 2023Feb 22, 2024May 1, 2024Aug 6, 2024Nov 5, 2024Feb 25, 2025May 13, 2025Aug 5, 2025Nov 5, 2025Mar 11, 2026May 12, 2026Aug 7, 2026Nov 4, 2026
EPS Estimate-2.80-13.01-3.71-4.19-3.28-3.12-2.48-2.64-2.36-1.64-2.00-2.24-2.56-2.08-3.04-2.07-3.15-3.08-2.84-2.85-3.33-3.01-3.04-2.86-2.32-1.83-1.531.71-1.39-1.76-1.50-1.52-1.68-1.41-0.92-1.63-0.44-0.77-0.88-1.20-0.97-1.01-1.05-1.07-0.90-0.35-0.30-0.14-0.01-0.14
EPS Actual-20.40-12.24-3.20-2.48-2.16-1.92-2.80-2.32-1.44-1.92-2.24-2.40-2.16-2.24-1.92-2.56-2.56-2.48-2.72-3.28-2.56-2.88-6.16-2.485.84-1.52-1.44-1.68-2.00-1.76-4.00-1.84-1.63-1.29-1.26-1.31-1.12-1.03-1.39-1.13-1.092.97-0.56-0.50-0.43-0.36-25.51-0.17-0.46-
Surprise-628.57%5.92%13.75%40.81%34.15%38.46%-12.90%12.12%38.98%-17.07%-12.00%-7.14%15.63%-7.69%36.84%-23.67%18.73%19.48%4.23%-15.09%23.12%4.32%-102.63%13.29%351.72%16.94%5.88%-198.25%-43.88%0.00%-166.67%-21.05%2.98%8.51%-36.96%19.63%-154.55%-33.77%-57.95%5.83%-12.37%394.06%46.67%53.27%52.22%-2.86%-8403.33%-23.19%-4500.00%-
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market---

Key Statistics & Ratios

Market Cap162.34M
Enterprise Value91.37M
Trailing P/E0.00
Forward P/E11.21
PEG Ratio0.00
Price / Sales1.87
Price / Book2.68
EPS-36.12
Book Value-4.52
Revenue (TTM)0
Gross Profit (TTM)-15.54M
EBITDA-28.53M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-675.09%
Return on Assets-28.42%
Shares Outstanding47.75M
Shares Float34.30M
Beta-0.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 10.33
  • Hold
    1

Ownership Breakdown

Institutions
93.31%
Insiders
3.26%
Retail / Other
3.43%

Top Institutional Holders

  • Federated Hermes Inc
    4.67M9.78%
  • Vivo Capital, LLC
    4.32M9.05%
  • HHG PLC
    4.29M8.99%
  • Balyasny Asset Management LLC
    4.26M8.92%
  • Logos Global Management LP
    3.29M6.89%
  • Farallon Capital Management, L.L.C.
    2.37M4.95%
  • Ally Bridge Group (NY) LLC
    2.18M4.56%
  • Foresite Capital Management VI LLC
    1.99M4.16%
  • Vanguard Capital Management, LLC
    1.85M3.87%
  • Spruce Street Capital LP
    1.66M3.47%
  • Adage Capital Partners Gp LLC
    1.42M2.97%
  • Trails Edge Capital Partners, LP
    1.42M2.97%
  • DV Trading LLC
    889.25K1.86%
  • Longwood Capital Partners LLC
    709.50K1.49%
  • BlackRock Inc
    624.86K1.31%
  • Millennium Management LLC
    533.60K1.12%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.41M2.95%
  • iShares Russell 2000 ETF
    641.67K1.34%
  • Federated Hermes Kaufmann Small Cap A
    502.49K1.05%
  • Federated Hermes Kaufmann R
    483.72K1.01%

Stock Splits

  • Jun 21, 20221:8